Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084071 · ClinicalTrials.gov registry record · Phase 3
Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,136
- Enrollment target
NCT00084071: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00084071 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,136 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (177% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00084071, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,136 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.
Interventions
- DRUG Tifacogin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,136 participants |
| Start Date | 2004-05 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
What the finished NCT00084071 record still lists
NCT00084071 is an interventional study that assigns participants to a tested intervention. Its 2,136 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (177% higher).
The record links to 0 conditions, and to 1 intervention - of which Tifacogin is the first listed.
NCT00084071 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00084071 about?
NCT00084071 is a clinical study titled "Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia". The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.
What is the current status of trial NCT00084071?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,136 participants. The study started on 2004-05. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00084071?
The interventions under investigation include: Tifacogin (DRUG).
Who is sponsoring clinical trial NCT00084071?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00084071's enrollment target sits among peer trials
2,136 97th of 2000 higher than 1,904 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05650658 · 2,136 participants · NA
Left vs Left Randomized Clinical Trial
- NCT03488693 · 2,140 participants · Phase 3
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
- NCT06598475 · 2,142 participants · NA
Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
- NCT07431281 · 2,130 participants · Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia